TY - JOUR T1 - Safety of 5914 intravitreal ziv-aflibercept injections JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 805 LP - 810 DO - 10.1136/bjophthalmol-2018-312453 VL - 103 IS - 6 AU - Sumit Randhir Singh AU - Michael W Stewart AU - Goura Chattannavar AU - Mohammed Ashraf AU - Ahmed Souka AU - Mazen ElDardeery AU - Neeraj Wadhwa AU - Chintan Sarvaiya AU - Ahmad M Mansour AU - Ameen Marashi AU - Suresh Ramchandani AU - Imoro Zeba Braimah AU - Mohammad Hossein Jabbarpoor Bonyadi AU - Alireza Ramezani AU - Masoud Soheilian AU - João Rafael de Oliveira Dias AU - Gabriel Costa de Andrade AU - André Maia AU - Eduardo Büchele Rodrigues AU - Michel Eid Farah AU - Alay Banker AU - Jay Chhablani A2 - , Y1 - 2019/06/01 UR - http://bjo.bmj.com/content/103/6/805.abstract N2 - Purpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related.Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent.Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders. ER -